<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib3">
 <label>3</label>
 <element-citation publication-type="journal" id="sref3">
  <person-group person-group-type="author">
   <name>
    <surname>Qureshi</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Yildirim</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Gasser</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Basmadjian</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Wilmet</surname>
    <given-names>J.P.</given-names>
   </name>
   <name>
    <surname>Desaubry</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Nebigil</surname>
    <given-names>C.G.</given-names>
   </name>
  </person-group>
  <article-title>FL3, a synthetic flavagline and ligand of prohibitins, protects cardiomyocytes via STAT3 from doxorubicin toxicity</article-title>
  <source>PloS One</source>
  <volume>10</volume>
  <year>2015</year>
  <object-id pub-id-type="publisher-id">e0141826</object-id>
 </element-citation>
</ref>
